



Memorandum

Date: September 7, 2026

To: Healthcare Practitioners

From: Insured Health Services

Subject: Formulary Updates – September 2026

Dear Healthcare Practitioner,

Insured Health Services is providing the following updates regarding the Yukon Drug Formulary and recent changes to coverage.

PrEP Medication:

- Insured Health Services recently distributed a memo to pharmacies outlining the process for applying for funding for PrEP (pre-exposure prophylaxis) medications.
- The memo outlining the funding application process can be found here: <https://yukon.ca/en/yukon-drug-plans-formulary-update>

Migraine Medications:

- Eligibility criteria for coverage of certain migraine medications have been updated to improve access for eligible patients.

The medications affected include:

- Topiramate
 - Ajovy (fremanezumab)
 - Emgality (galcanezumab)
 - Vyepti (eptinezumab)
 - Qulipta (atogepant)
- Please refer to the **Yukon Drug Formulary** for the most current eligibility and coverage criteria: <https://apps.gov.yk.ca/apexprd/r/drug/drug-formulary-public/home>

Ofev Generics:

- Effective **August 18, 2026**, generic versions of Ofev (nintedanib) have been added to the Yukon Drug Formulary.
- **Lower Cost Alternative (LCA)** has also been added for Ofev. Coverage will therefore be subject to the applicable LCA requirements.

Contact Information

For questions or additional information, please contact:

Chronic Disease and Disability Benefits

867-667-5092

Pharmacare and Extended Benefits

867-667-5403 or 867-667-8494

Thank you for your attention to these formulary updates.